BioRestorative Therapies, Inc. (BRTX)
| Market Cap | 13.02M |
| Revenue (ttm) | 391,000 |
| Net Income (ttm) | -12.10M |
| Shares Out | 7.50M |
| EPS (ttm) | -1.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,461 |
| Open | 1.780 |
| Previous Close | 1.750 |
| Day's Range | 1.710 - 1.780 |
| 52-Week Range | 1.030 - 2.550 |
| Beta | 77.48 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+937.46%) |
| Earnings Date | May 14, 2025 |
About BRTX
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company’s products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to ... [Read more]
Financial Performance
In 2024, BioRestorative Therapies's revenue was $401,000, an increase of 175.03% compared to the previous year's $145,800. Losses were -$8.98 million, -13.81% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BRTX stock is "Strong Buy" and the 12-month stock price forecast is $18.0.
News
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2025 Earnings Call May 14, 2025 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Lance Alstodt - Chairman and Chief Executive Office...
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on...
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on...
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on...
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities
MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused ...
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States
MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused...
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Exe...
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting –
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused ...
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May also lead ...
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
– Covers cGMP manufacturing processes – – Expected to provide protection until April 29, 2040 – MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief ...
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research –
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a regenerative medicine innovator focused on stem cell-ba...
BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused ...
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:03 PM ET BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q2 2024 Earnings Conference Call August 13, 2024, 16:30 PM ET Company Participants Lance Alstodt - President,...
BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorat...
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform –
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRest...
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders –
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today...
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therap...
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to ...
BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Stephen Kilmer - Head of Investor Relations Lance Alstodt - President, Chief...
BioRestorative Therapies Provides First Quarter 2024 Business Update
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapi...